Translational Development Acquisition Corp. Ordinary Shares Total Assets
Translational Development Acquisition Corp. Ordinary Shares total assets. Based on the latest financial reports, Translational Development Acquisition Corp. Ordinary Shares (TDAC) holds total assets worth $157.37 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Translational Development Acquisition Co (TDAC) total market value for the company's overall valuation and market capitalisation.
Total Assets of Translational Development Acquisition Corp. Ordinary Shares (2022–2025)
Total assets of Translational Development Acquisition Corp. Ordinary Shares from 2022 to 2025. This chart illustrates how Translational Development Acquisition Corp. Ordinary Shares's total assets have evolved over time, based on quarterly financial data. See TDAC share price today for real-time trading data and today's change.
Translational Development Acquisition Corp. Ordinary Shares - Asset Composition Analysis
Translational Development Acquisition Corp. Ordinary Shares Total Assets Breakdown (December 2025)
Translational Development Acquisition Corp. Ordinary Shares total assets breakdown as of December 2025. Translational Development Acquisition Corp. Ordinary Shares's total assets of $157.37 Million consist of 0.0% current assets and 100.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Translational Development Acquisition Corp. Ordinary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Translational Development Acquisition Co to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Translational Development Acquisition Corp. Ordinary Shares's current assets represent 0.0% of total assets in 2025, a decrease from 12.4% in 2022.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2025, down from 0.5% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Translational Development Acquisition Corp. Ordinary Shares Competitors by Total Assets
Key competitors of Translational Development Acquisition Corp. Ordinary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Churchill Capital Corp IX
NASDAQ:CCIX
|
USA | $310.55 Million |
|
Roman DBDR Acquisition Corp. II Unit
NASDAQ:DRDBU
|
USA | $241.51 Million |
|
BTC Development Corp.
NASDAQ:BDCI
|
USA | $260.91 Million |
|
Range Capital Acquisition Corp II Class A Ordinary Shares
NASDAQ:RNGT
|
USA | $237.20 Million |
|
ITHAX Acquisition Corp III Class A Ordinary Shares
NASDAQ:ITHA
|
USA | $30.90K |
|
Fortress Value Acquisition Corp. V Class A Ordinary Shares
NASDAQ:FVAV
|
USA | $292.17 Million |
|
Solarius Capital Acquisition Corp.
NASDAQ:SOCA
|
USA | $180.29 Million |
|
Apogee Acquisition Corp Class A Ordinary Shares
NASDAQ:AACP
|
USA | $175.36 Million |
Translational Development Acquisition Corp. Ordinary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.06 | 0.55 | 0.61 |
| Quick Ratio | 0.06 | 0.55 | 0.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.65 Million | $-128.60K | $-40.30K |
Translational Development Acquisition Corp. Ordinary Shares - Advanced Valuation Insights
This section examines the relationship between Translational Development Acquisition Corp. Ordinary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.40 |
| Latest Market Cap to Assets Ratio | 1.15 |
| Asset Growth Rate (YoY) | 3.8% |
| Total Assets | $181.70 Million |
| Market Capitalization | $208.88 Million USD |
Valuation Analysis
Above Book Valuation: The market values Translational Development Acquisition Corp. Ordinary Shares's assets above their book value (1.15x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Translational Development Acquisition Corp. Ordinary Shares's assets grew by 3.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Translational Development Acquisition Corp. Ordinary Shares (2022–2025)
The table below shows the annual total assets of Translational Development Acquisition Corp. Ordinary Shares from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $181.70 Million | +3.83% |
| 2024-12-31 | $175.00 Million | +8659008.31% |
| 2023-12-31 | $2.02K | -99.54% |
| 2022-12-31 | $437.24K | -- |
About Translational Development Acquisition Corp. Ordinary Shares
Translational Development Acquisition Corp. does not have significant operations. The company intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.